Jennifer Bath is the CEO and President of IPA. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.
Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. There, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology, and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.
Connect with Jennifer on LinkedIn
Reena Patel, Health and Science Writer
Working exclusively in health communications for more than 24 years, Reena Patel is passionate about elevating the researchers, companies, and health breakthroughs that advance medicine and address the unmet needs of patients. Reena’s experience extends to covering regulatory and clinical milestones, explaining complex research technology and study design, and translating research outcomes for professional and lay audiences.
Connect with Reena on LinkedIn
Interview questions:
Q1: IPA is doing some really exciting and innovative work in the therapeutic antibody space, especially with how you’re integrating AI to tackle drug discovery challenges. For listeners who might not be familiar, can you share a bit more about what IPA does and how your approach is reshaping the way therapies are developed?
Q2: The field of therapeutic discovery is moving so quickly—it feels like there’s always something new and groundbreaking happening. From your perspective, what’s the most exciting development in the industry right now? And how is IPA focusing its efforts in the year ahead to stay at the forefront of innovation?
Q3: Despite the challenging funding environment in recent years, it’s inspiring to see so many early to mid-stage biotech companies continuing to innovate and push boundaries. Dr. Bath, let’s take a moment to talk about the market landscape. With therapeutic antibody development growing so rapidly, what does the market size and opportunity look like right now? And how is IPA navigating this environment and positioning itself for success?
Q4: Dr. Bath, I know IPA has a strong interest in AI-driven drug development, particularly with a focus on oncology. Why is that an area of focus for the company? And what can you tell us about the impact IPA is making in this space, especially when it comes to leveraging AI to tackle some of the most complex challenges in cancer treatment?
Q5: Earlier this month, you attended the annual JP Morgan Healthcare Conference, one of the largest and most influential healthcare investment symposiums, bringing together global industry leaders and innovators. Was there anything new or particularly interesting that stood out to you? Any trends or development areas you saw that look especially promising for the biotech space?
Q6: Dr. Bath, biotech can be such a complex and rapidly evolving field, and sometimes it feels like there’s a gap between what’s happening on the ground and how it’s perceived by investors. What do you wish investors understood better about what IPA is doing and the broader state of the biotech industry right now?
Q7: Dr. Bath, thank you for taking the time to speak with us. This has been such an insightful conversation. Before we wrap up, is there anything else you’d like to share with our listeners? And for those who want to learn more about IPA and the work you’re doing, what’s the best way for them to stay connected or get more information?
ImmunoPrecise Antibodies (IPA) is a global leader in innovative therapeutic antibody discovery and development. With cutting-edge facilities and advanced technologies, IPA partners with pharmaceutical, biotechnology, and academic organizations to tackle complex drug discovery challenges. Their comprehensive approach integrates humanized platforms, state-of-the-art AI capabilities, and proprietary technologies to accelerate the development of safer and more effective biologics. By combining expertise in antibody engineering and AI-driven analysis, IPA aims to reduce development timelines and costs while improving patient outcomes. Their mission is to revolutionize therapeutic discovery, enabling next-generation solutions in life sciences and healthcare.
Recent News: https://www.ipatherapeutics.com/news
Edwin Warfield, CEO of citybizlist, conducts CEO Interviews.
If you’re interested in a citybiz CEO Interview, please contact
Edwin Warfield – edwin.warfield@citybizlist.com